Trv Gp Iv 13F annual report
Trv Gp Iv is an investment fund managing more than $202 billion ran by Kevin Gillis. There are currently 3 companies in Mr. Gillis’s portfolio. The largest investments include Tango Therapeutics, Inc. and Pliant Therapeutics, together worth $188 billion.
$202 billion Assets Under Management (AUM)
As of 2nd August 2024, Trv Gp Iv’s top holding is 19,201,475 shares of Tango Therapeutics, Inc. currently worth over $165 billion and making up 81.5% of the portfolio value.
In addition, the fund holds 2,132,867 shares of Pliant Therapeutics worth $22.9 billion, whose value fell 22.6% in the past six months.
The third-largest holding is Fulcrum Therapeutics Inc worth $14.5 billion.
Currently, Trv Gp Iv's portfolio is worth at least $202 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Trv Gp Iv
The Trv Gp Iv office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, Kevin Gillis serves as the Chief Operating Officer at Trv Gp Iv.
Recent trades
There are companies that Trv Gp Iv is getting rid of from its portfolio.
Trv Gp Iv closed its position in Revolution Medicines Inc on 9th August 2024.
It sold the previously owned 1,419,900 shares for $28 million.
Kevin Gillis also disclosed a decreased stake in Tango Therapeutics, Inc. by approximately 0.1%.
This leaves the value of the investment at $165 billion and 19,201,475 shares.
One of the smallest hedge funds
The two most similar investment funds to Trv Gp Iv are Codex Capital, L.L.C and Pine Brook Road Advisors, L.P.. They manage $202 billion and $202 billion respectively.
Kevin Gillis investment strategy
Trv Gp Iv’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 18.5% of
the total portfolio value.
The fund focuses on investments in the United States as
66.7% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $609 million.
The complete list of Trv Gp Iv trades based on 13F SEC filings
These positions were updated on August 9th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Tango Therapeutics, Inc. |
0.84%
19,201,475
|
$164,748,656,000 | 81.48% |
| Pliant Therapeutics, Inc. |
No change
2,132,867
|
$22,928,320,000 | 11.34% |
| Fulcrum Therapeutics Inc |
No change
2,343,154
|
$14,527,555,000 | 7.18% |
| Revolution Medicines Inc |
Closed
1,419,900
|
$28,000,000 | |
| Magenta Therapeutics Inc |
Closed
6,758,204
|
$9,529,000 | |
| No transactions found | |||
| Showing first 500 out of 5 holdings | |||
Hedge funds similar to Trv Gp Iv
- Investors Asset Management Of Georgia Inc ga adv
- Pavion Blue Capital
- Investment Partners, Ltd
- Hyperion Capital Advisors L.P.
- Vci Wealth Management
- Pine Brook Road Advisors, L.P.
- Codex Capital, L.L.C
- Bkm Wealth Management
- True Wind Capital Management, L.P.
- Teramo Advisors
- Once Capital Management
- Matisse Capital
- Sona Asset Management (us)
- Lakeshore Planning